Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Posts 26 Percent Rise in Q3 Revenues

NEW YORK (GenomeWeb News) – NeoGenomics today reported third-quarter revenue growth of 26 percent year over year.

For the three months ended Sept. 30, the Ft. Meyers, Fla.-based cancer genetic testing firm said that revenues rose to $14.2 million from $11.3 million a year ago. The number of tests performed in the quarter increased to 28,315 from 19,977, but the average revenue per test dipped to $501.58 from $566.66.

The decrease resulted from the expiration of the Medicare Technical Component Grandfather Clause on June 30, leading to an estimated reduction in revenue of $1.3 million, NeoGenomics said.

Its R&D spending spiked to $808,000 from $125,000 a year ago, and SG&A costs of $5.8 million represented an 18 percent increase from $4.9 million for the third quarter a year ago.

NeoGenomics' net loss widened to $975,000, or $.02 per share, in the quarter from a net loss of $143,000, or break-even, a year ago.

NeoGenomics finished the quarter with $2.0 million in cash and cash equivalents, and $300,000 in restricted cash.

For the fourth quarter, the company forecast revenue of between $14.3 million and $15.0 million and per-share figures of between break-even and a net loss of $.01. Full-year revenue estimates were narrowed to a range of $59 million to $60 million from an earlier range of $57 million to $63 million.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.